Venezuelan equine encephalitis (VEE) is a reemerging, mosquito-borne viral disease of the neotropics that is severely debilitating and sometimes fatal to humans. Periodic epidemics mediated by equine amplification have been recognized since the 1920s, but interepidemic disease is rarely recognized. We report here clinical findings and genetic characterization of 42 cases of endemic VEE detected in Panama from 1961–2004. Recent clusters of cases occurred in Darien (eastern Panama) and Panama provinces (central Panama) near rainforest and swamp habitats. Patients ranged from 10 months to 48 years of age, and the more severe cases with neurological complications, including one fatal infection, were observed in children. The VEE virus strains isolated from these cases all belonged to an enzootic, subtype ID lineage known to circulate among sylvatic vectors and rodent reservoir hosts in Panama and Peru. These findings underscore endemic VEE as an important but usually neglected arboviral disease of Latin America.
Venezuelan equine encephalitis (VEE) is a mosquito-borne viral disease that has caused major epidemics in many parts of Latin America and has even spread into Texas on one occasion. These epidemics result from spillover to humans of a horse-mosquito-horse amplification cycle that has occurred periodically since the 1920s. However, between these equine-mediated epidemics, little attempt is typically made to detect VEE in humans. Here, we show that VEE virus strains that typically circulate in a mosquito-rodent cycle, termed enzootic strains, also produce many cases of severe and sometimes fatal disease in Panama in the absence of apparent epidemics. These endemic infections are probably rarely detected because they are difficult to distinguish clinically from dengue fever, another mosquito-borne viral illness common in the tropics. Our findings underscore endemic VEE as an important but usually neglected arboviral disease of Latin America.
Citation: Quiroz E, Aguilar PV, Cisneros J, Tesh RB, Weaver SC (2009) Venezuelan Equine Encephalitis in Panama: Fatal Endemic Disease and Genetic Diversity of Etiologic Viral Strains. PLoS Negl Trop Dis 3(6): e472. https://doi.org/10.1371/journal.pntd.0000472
Editor: Scott B. Halstead, Pediatric Dengue Vaccine Initiative, United States of America
Received: March 16, 2009; Accepted: May 28, 2009; Published: June 30, 2009
Copyright: © 2009 Quiroz et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This research was supported by National Institutes of Health Grants AI48807 and AI071192, McLaughlin Fellowship Fund (http://research.utmb.edu/intramural_funding/index.htm), and Adan Rios Foundation (http://www.taxexemptworld.com/organization.asp?tn=1130532). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Venezuelan equine encephalitis virus (VEEV) is the most important alphaviral (Togaviridae: Alphavirus) pathogen of humans and domestic animals in the western hemisphere ,. Most human and animal disease occurs when VEEV undergoes an amplification cycle where equids (horses, donkeys and mules) become infected and develop high titer viremia, facilitating transmission by Aedes and Psorophora spp. mosquitoes to susceptible equids or people. The VEEV strains involved in this equid amplification cycle belong to subtypes IAB and IC, and are called epizootic or epidemic (henceforth called epidemic). These strains arise periodically and repeatedly via mutation of enzootic VEEV subtypes . The resulting epidemics typically involve tens-to-hundreds of thousands of cases in humans and equids. Human disease is highly debilitating and immunosuppressive, and occasionally fatal (less than 1% of cases); however, many persons, especially children, suffer permanent neurological sequelae ,. In equids, VEEV causes mortality in roughly half of infected animals, resulting in major effects on agricultural activities that rely on these animals in many parts of Latin America.
The progenitors of the epidemic VEEV strains are called enzootic viruses, are not associated with equine disease, and circulate more or less continuously in forested or swamp habitats where rodents serve as the reservoir hosts and mosquitoes in the subgenus Culex (Melanoconion) act as vectors . These enzootic strains were first isolated in the 1950's, and a fatal human isolate made in Panama in 1961  was later identified as a subtype ID enzootic strain. The enzootic VEEV cycle, which involves subtypes ID and IE, often goes undetected because these viruses are incapable of exploiting these hosts for amplification to produce widespread disease ,. However, enzootic VEEV strains are increasingly recognized as important endemic pathogens of people who live near the enzootic transmission foci and/or enter the habitats where enzootic circulation occurs ,,. Because human VEE is nearly impossible to distinguish clinically from other tropical viral diseases such as dengue, most cases are probably undiagnosed. Endemic VEE is therefore grossly underreported in many parts of the Americas where enzootic circulation occurs and surveillance for febrile illness is limited.
To further characterize human disease caused by enzootic VEEV, we studied 42 cases of VEEV infection characterized by virus isolation, some accompanied by neurological disease, detected in Panama from 1961–2004. Here we describe the clinical signs and symptoms of disease, ecological conditions accompanying VEEV exposure and genetic characterizations of the etiologic VEEV strains.
VEEV isolates from infected persons, included in the study, are shown in Table 1. The retrospective analyses of these isolates and reporting of clinical data were approved by the Institutional Review Boards of the Gorgas Memorial Institute and the University of Texas Medical Branch. Most of the viruses were isolated in Vero cells or by intracerebral inoculation of newborn mouse brains with sera from febrile patients, with triturated mosquito pools, or with rodent tissues (approved by the institutional animal care and use committees of the Gorgas Memorial Institute and the University of Texas Medical Branch). Supernatant fluids from infected cells or brain homogenates were stored at −70°C and later used for the extraction of viral RNA.
To determine the viremia levels in infected patients, available sera were tested by plaque assay as previously described  using Vero cells.
Viral RNA extraction and cDNA synthesis
RNA was extracted from virus stocks as described previously . A 250 µl volume of the 10% homogenized mouse brain tissue or supernatant was mixed with 750 µl of Trizol LS (Gibco-BRL, Gaithersburg, MD) and RNA was extracted following the manufacturer's protocol. Synthesis of cDNA was performed by mixing 5 µl of the RNA (1/10th of the extracted RNA) with 1 µmol of reverse primer V9207B(−), 1× First Strand Buffer (Gibco), 1 mM dNTPs, 80 U RNAsin (Promega, Madison, WI) and 200 U SuperScript II Reverse Transcriptase (Gibco). The reaction was incubated at 42°C for 1 h.
PCR amplification, sequencing and phylogenetic analysis
PCR was carried out using primers V8369(+) (GAGAACTGCGAGCAATGGTCA) and V9207B(−) (TRCACTGGCTGAACTGTT) as previously described . These primers amplify the N-terminus of the PE2 envelope glycoprotein precursor gene, a region that has been used extensively in VEEV phylogenetic analyses ,, and is known to undergo critical amino acid substitutions associated with epidemic VEEV emergence . The 816 bp PCR product was sequenced directly using primers V8659 (AATTGAGGCAGTGAAGAGCGAC) and V8953B (CTGCCTACAGGATTAAAT) using an Applied Biosystems (Foster City, CA) Prism automated DNA sequencing kit following the manufacturer's protocol. Sequences were aligned using MacVector program (Oxford Molecular Group, Campbell, CA) and phylogenetic analyses were performed using the maximum parsimony and neighbor joining programs implemented in the PAUP 4.0 software  or with MrBayes 3.0  with 1,000,000 iterations. Bootstrap analyses were conducted using neighbor joining with 1,000 replicates to place confidence values on grouping within the trees .
Distribution of the VEEV cases in Panama
Data from recent VEE cases we studied (1990–2004) were compared with those from the literature dating to 1961. Recent VEE cases in Panama were reported in the provinces of Darien, Panama, Cocle, Veraguas and Bocas del Toro (Figure 1). Two clusters of cases were observed - one covering the Darien province and the second covering Panama Province (central Panama). Darien, the largest and most sparsely populated of the regions, extends from the hinterlands of Panama Province to the Colombian border, comprising more than one-third of the national territory. The land in Darien is characterized by forest and swamps and thus includes large areas of habitat for the Culex (Melanoconion) vectors of enzootic VEEV and small rodents that serve as the principal reservoir host . The second cluster of cases was observed in Panama Province, between Gatun and Bayano Lakes. The surrounding area is characterized by rainforest and swamps habitats and is also conducive to enzootic VEEV circulation ,,,. Cases of VEE in Panama were reported in patients whose age ranged from 10 months to 48 years old. The more severe cases with neurological complications were observed in children.
Description of the VEE cases
The VEE cases we studied, as well as those previously reported and included here for comparative purposes, were characterized by fever, headache, tremors, nausea, vomiting and diarrhea (Table 1). Only 3 of the cases developed neurological complications, and 2 of these were fatal. All cases of neurological disease were children less than 15 years of age. Overall, the most common signs and symptoms among the 33 VEE patients for which data were available included fever (94%), headache (55%), retroorbital pain (27%) and tremors (27%)(Table 2). These common signs and symptoms would not distinguish VEE from a wide variety of other tropical diseases, including malaria and dengue, without laboratory diagnostics. The overall case fatality rate of the Panamanian cases with known outcomes was 2/39, or 5% (Table 1). This rate is higher than that reported during most VEE epidemics (typically less than 1%) , which could reflect greater recognition of milder cases when more active surveillance is being conducted during outbreaks.
To investigate whether humans infected with subtype ID enzootic VEEV develop viremia titers sufficient to infect potential mosquito vectors, we quantified the virus titers in the sera of 5 patients (the only ones from which virus was isolated that were still available) using plaque assay. Titers varied from 3.0×102 to 6.7×105 PFU/ml (Table 3). Because the sera may not have been sampled at the time of peak viremia, these titers may underestimate maximum viremia levels.
To investigate genetic relationships among the VEEV strains from Panama in comparison to others isolated from different regions of the Americas, phylogenetic analyses were performed. Maximum parsimony, neighbor joining and Bayesian methods all generated similar tree topologies. The neighbor-joining tree based on the partial PE2 sequences (Figure 2) showed that most of the subtype ID VEEV strains from Panama formed a single clade, with previously sequenced Panamanian subtype ID strains as well as some Peruvian ID isolates. This group was previously called the Panama-Peru subtype ID genotype . Within this group, 2 distinct clades among the Panamanian strains were observed: 1) strains from Central Panama; 2) isolates from Eastern Panama (Darien). The final subtype ID isolate, strain 213391 from western Panama (Bocas del Toro Province), was phylogenetically distinct from all other ID isolates. Our phylogenies placed it outside of the Panama/Peru genotype, but this placement was supported by a bootstrap value of only 69%. The location of collection of this strain was geographically close to those of subtype IE strains isolated in the 1960s (Fig. 2). Therefore, the geographic ranges of subtypes ID and IE may overlap slightly.
The tree was produced using the neighbor joining program implemented in PAUP 4.0 . VEEV strains are denoted by abbreviated country and year of isolation, followed by strain designation. Panamanian strains include abbreviated province in parentheses as follows: BT – Bocas del Toro; COC – Cocle; COL – Colon; DA – Darien; PA – Panama; VE – Veraguas. Numbers indicate bootstrap values for clades.
In 1961, the first evidence of VEEV in Panama was obtained when the virus was isolated from a fatal human case. The patient, a 14-year-old boy, resided in Cañito, near Gatun lake . Since then, febrile disease associated with VEEV has been reported in the vicinity of Gatun and Bayano Lakes and in the province of Darien, all areas of rainforest and swamp habitat. Our results indicate that VEEV infection in at least 2 regions of Panama may be common, and the clinical features of the disease evaluated in 33 acute individuals suggest that only laboratory diagnostics can distinguish VEE from other febrile, tropical diseases such as malaria, dengue and Mayaro fever that present with overlapping signs and symptoms. Thus, the incidence of VEE in Panama and other endemic regions of Latin America is probably grossly underreported because malaria and dengue are assumed to be the etiologies of all febrile illnesses in the absence of laboratory diagnostics. Because exposure to VEEV involves vectors with different temporal and spatial distributions than those of dengue and malaria ,, improved VEE diagnosis could lead to better prevention methods to reduce human exposure.
For subtype ID VEEV, the highest viremia titers that we measured in infected persons are presumably capable of orally infecting and being transmitted by several mosquito species including the proven subtype IE enzootic VEEV vector Cx. (Mel.) taeniopus , and the proven and potential epidemic VEEV vectors Psorophora confinnis , Ae. taeniorhynchus ,, Ae. albopictus  and Ae. aegypti . Although infection thresholds have not been determined for natural, enzootic subtype ID vectors, we believe that it is likely that they could be infected by feeding on persons with titers on the order that we measured. Furthermore, serum titers and mosquito transmission potential could be even higher if the individuals we studied were not sampled at the peak of viremia. Previous studies have reported that horses infected with epidemic VEEV strains develop comparable viremia levels, which allow them to serve as highly efficient amplifying hosts by infecting susceptible mosquitoes ,,. These results suggest the possibility that humans infected with subtype ID VEEV in Panama could support an epidemic human-mosquito-human transmission cycle, especially if a viremic individual reached an urban area with abundant Ae. aegypti or Ae. albopictus. These species, especially the former, are highly efficient vectors of other human arboviruses such as dengue  and chikungunya  due to their ecology and behavior as well as their susceptibility to infection. Interestingly, VEE is endemic in Iquitos, Peru, where Ae. aegypti is abundant and transmits DENV to thousands of people during epidemics. However, the average number of diagnosed VEE human cases per year in Peru is about ten, but this is probably a gross underestimate of the true number (P.V. Aguilar, unpublished). Because VEEV viremia in humans is high enough to infect Ae. aegypti, regular human VEE outbreaks in Iquitos might be expected. However, only one VEE human outbreak has been reported in Iquitos (in 2006)  despite detection of endemic VEE there since 1993 . Thus, additional factors not yet understood may be crucial to the emergence of enzootic VEE. Mutations that arise during the adaptation of the virus to certain mosquito species have been previously described as a key factor in the epizootic VEE emergence, and thus deserve further study ,. Other factors such as mosquito abundance should also be investigated.
Hemorrhagic manifestations among VEE cases are rare. To date, only two patients (<15 years of age) have been reported with hemorrhagic complications upon VEEV infection with the subtype ID Panama/Peru genotype . Interestingly, one of the VEE patients from Panama that we studied also reported hemorrhagic manifestations and encephalitis, although the former was not determined to be the cause of death. Thus, although hemorrhages associated with VEEV infection are unusual, they do occur and their potential role in a fatal outcome should be investigated.
One of the Panamanian patients infected with VEEV from 1990–2004 developed a fatal encephalitic disease, further confirming that subtype ID Panama/Peru genotype can cause fatal disease. Although subtype ID Panama/Peru lineage strains have been continuously associated with human illness in Peru, fatal disease has never been reported there despite many cases in children . The reasons for this lack of fatal VEE in Peru remain unknown, but could include underreporting in many locations where laboratory diagnosis is not readily available.
Our phylogenetic analyses revealed that all Panamanian isolates with one exception belong to the previously described Panama/Peru genotype ,. Within this group, 2 distinct clades among the Panamanian strains were observed: one sampled from Central Panama, and a second from Eastern Panama (Darien). A third Panamanian ID lineage was identified in western Panama (Bocas del Toro), which may represent a new, major lineage in subtype ID. Longer sequences may be needed to definitively determine the relationship of this new lineage to the other ID genotypes. Interestingly, this Bocas del Toro isolate was recovered from a patient who presented with encephalitis and hemorrhagic complications. Thus, further studies are needed to investigate whether this specific genotype is particularly associated with severe encephalitis and hemorrhagic disease. In addition, future genetic analyses of the Panamanian and Peruvian isolates associated with hemorrhagic disease could provide important insights about the viral determinants (if any) of this infrequent disease manifestation. Potential host factors/conditions should also be investigated for their role in disease outcome.
Conceived and designed the experiments: EQ PVA JC RBT SCW. Performed the experiments: EQ PVA. Analyzed the data: EQ PVA SCW. Contributed reagents/materials/analysis tools: EQ JC SCW. Wrote the paper: EQ PVA RBT SCW.
- 1. Weaver SC, Ferro C, Barrera R, Boshell J, Navarro JC (2004) Venezuelan equine encephalitis. Annu Rev Entomol 49: 141–174.
- 2. Walton TE, Grayson MA (1988) Venezuelan equine encephalomyelitis. In: Monath TP, editor. The Arboviruses: Epidemiology and Ecology, Vol IV. Boca Raton, Florida: CRC Press. pp. 203–231.
- 3. Powers AM, Oberste MS, Brault AC, Rico-Hesse R, Schmura SM, et al. (1997) Repeated emergence of epidemic/epizootic Venezuelan equine encephalitis from a single genotype of enzootic subtype ID virus. J Virol 71: 6697–6705.
- 4. Johnson KM, Martin DH (1974) Venezuelan equine encephalitis. Adv Vet Sci Comp Med 18: 79–116.
- 5. Anishchenko M, Bowen RA, Paessler S, Austgen L, Greene IP, et al. (2006) Venezuelan encephalitis emergence mediated by a phylogenetically predicted viral mutation. Proc Natl Acad Sci U S A 103: 4994–4999.
- 6. Johnson KM, Shelokov A, Peralta PH, Dammin GJ, Young NA (1968) Recovery of Venezuelan equine encephalomyelitis virus in Panama. A fatal case in man. Am J Trop Med Hyg 17: 432–440.
- 7. Johnson KM, Shelokov A, Peralta PH, Dammin GJ, Young NA (1968) Recovery of Venezuelan equine encephalomyelitis virus in Panama. A fatal case in man. Am J Trop Med Hyg 17: 432–440.
- 8. Aguilar PV, Greene IP, Coffey LL, Medina G, Moncayo AC, et al. (2004) Endemic Venezuelan equine encephalitis in northern Peru. Emerg Infect Dis 10: 880–888.
- 9. Powers AM, Brault AC, Kinney RM, Weaver SC (2000) The use of chimeric Venezuelan Equine Encephalitis viruses as an approach for the molecular identification of natural virulence determinants. Journal of Virology 74: 4258–4263.
- 10. Weaver SC, Pfeffer M, Marriot K, Kang W, Kinney RM (1999) Genetic evidence for the origins of Venezuelan equine encephalitis virus subtype IAB outbreaks. Am J Trop Med Hyg 60: 441–448.
- 11. Oberste MS, Weaver SC, Watts DM, Smith JF (1998) Identification and genetic analysis of Panama-genotype Venezuelan equine encephalitis virus subtype ID in Peru. Am J Trop Med Hyg 58: 41–46.
- 12. Watts DM, Callahan J, Rossi C, Oberste MS, Roehrig JT, et al. (1998) Venezuelan equine encephalitis febrile cases among humans in the Peruvian Amazon River region. Am J Trop Med Hyg 58: 35–40.
- 13. Swofford DL (1998) PAUP*. Phylogenetic Analysis Using Parsimony (*and Other Methods). Version 4. Sunderland, Massachusetts: Sinauer Associates.
- 14. Ronquist F, Huelsenbeck JP (2003) MrBayes 3: Bayesian phylogenetic inference under mixed models. Bioinformatics 19: 1572–1574.
- 15. Felsenstein J (1985) Confidence limits on phylogenies: An approach using the bootstrap. Evolution 39: 783–791.
- 16. Salas RA, Garcia CZ, Liria J, Barrera R, Navarro JC, et al. (2001) Ecological studies of enzootic Venezuelan equine encephalitis in north-central Venezuela, 1997–1998. Am J Trop Med Hyg 64: 84–92.
- 17. Franck PT, Johnson KM (1970) An outbreak of Venezuelan encephalitis in man in the Panama Canal Zone. Am J Trop Med Hyg 19: 860–865.
- 18. Dietz WH Jr, Peralta PH, Johnson KM (1979) Ten clinical cases of human infection with venezuelan equine encephalomyelitis virus, subtype I-D. Am J Trop Med Hyg 28: 329–334.
- 19. Mangiafico JA, Rossi CA, Ludwig GV (2002) Short report: Isolation and identification of Venezuelan equine encephalitis virus from a human in Panama. Am J Trop Med Hyg 67: 112–113.
- 20. Smith DW, Mackenzie JS, Weaver SC (2009) Alphaviruses. In: Richman DD, Whitley RJ, Hayden FG, editors. Clinical Virology. Washington, D.C.: ASM Press. pp. 1241–1274.
- 21. Oberste MS, Weaver SC, Watts DM, Smith JF (1998) Identification and genetic analysis of Panama-genotype Venezuelan equine encephalitis virus subtype ID in Peru. Am J Trop Med Hyg 58: 41–46.
- 22. Weaver SC, Tesh RB, Shope RE (2006) Alphavirus infections. In: Guerrant RI, Walker DH, Weller PF, editors. Tropical Infectious Diseases Principles, Pathogens and Practice, 2nd Edition. Philadelphia: Elsevier Churchill Livingstone. pp. 831–838.
- 23. Scherer WF, Cupp EW, Lok JB, Brenner RJ, Ordonez JV (1981) Intestinal threshold of an enzootic strain of Venezuelan equine encephalomyelitis virus in Culex (Melanoconion) taeniopus mosquitoes and its implication to vector competency and vertebrate amplifying hosts. Am J Trop Med Hyg 30: 862–869.
- 24. Ortiz DI, Anishchenko M, Weaver SC (2005) Susceptibility of Psorophora confinnis (Diptera: Culicidae) to infection with epizootic (subtype IC) and enzootic (subtype ID) Venezuelan Equine encephalitis viruses. J Med Entomol 42: 857–863.
- 25. Brault AC, Powers AM, Weaver SC (2002) Vector infection determinants of Venezuelan equine encephalitis virus reside within the E2 envelope glycoprotein. J Virol 76: 6387–6392.
- 26. Ortiz DI, Weaver SC (2004) Susceptibility of Ochlerotatus taeniorhynchus (Diptera: Culicidae) to infection with epizootic (subtype IC) and enzootic (subtype ID) Venezuelan equine encephalitis viruses: evidence for epizootic strain adaptation. J Med Entomol 41: 987–993.
- 27. Fernandez Z, Moncayo AC, Carrara AS, Forattini OP, Weaver SC (2003) Vector competence of rural and urban strains of Aedes (Stegomyia) albopictus (Diptera: Culicidae) from Sao Paulo State, Brazil for IC, ID, and IF subtypes of Venezuelan equine encephalitis virus. J Med Entomol 40: 522–527.
- 28. Ortiz DI, Kang W, Weaver SC (2008) Susceptibility of Ae. aegypti (Diptera: Culicidae) to infection with epidemic (subtype IC) and enzootic (subtypes ID, IIIC, IIID) Venezuelan equine encephalitis complex alphaviruses. J Med Entomol 45: 1117–1125.
- 29. Wang E, Bowen RA, Medina G, Powers AM, Kang W, et al. (2001) Virulence and viremia characteristics of 1992 epizootic subtype IC Venezuelan equine encephalitis viruses and closely related enzootic subtype ID strains. Am J Trop Med Hyg 65: 64–69.
- 30. Walton TE, Alvarez O Jr, Buckwalter RM, Johnson KM (1973) Experimental infection of horses with enzootic and epizootic strains of Venezuelan equine encephalomyelitis virus. J Infect Dis 128: 271–282.
- 31. Kissling RE, Chamberlain RW, Nelson DB, Stamm DD (1956) Venezuelan equine encephalomyelitis in horses. Am J Hyg 63: 274–287.
- 32. Gubler DJ (2004) The changing epidemiology of yellow fever and dengue, 1900 to 2003: full circle? Comp Immunol Microbiol Infect Dis 27: 319–330.
- 33. Powers AM, Logue CH (2007) Changing patterns of chikungunya virus: re-emergence of a zoonotic arbovirus. J Gen Virol 88: 2363–2377.
- 34. Brault AC, Powers AM, Ortiz D, Estrada-Franco JG, Navarro-Lopez R, et al. (2004) Venezuelan equine encephalitis emergence: Enhanced vector infection from a single amino acid substitution in the envelope glycoprotein. Proc Natl Acad Sci USA 101: 11344–11349.
- 35. Vilcarromero S, Laguna-Torres VA, Fernandez C, Gotuzzo E, Suarez L, et al. (2009) Venezuelan equine encephalitis and upper gastrointestinal bleeding in child. Emerg Infect Dis 15: 323–325.
- 36. Oberste MS, Schmura SM, Weaver SC, Smith JF (1999) Geographic distribution of Venezuelan equine encephalitis virus subtype IE genotypes in Central America and Mexico. Am J Trop Med Hyg 60: 630–634.